SECONDARY ACUTE MYELOID LEUKEMIA

This study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…

This study is for people with high-risk acute leukemia or myelodysplastic syndrome (MDS). It tests a new way to prepare the body for a donor stem cell transplant by combining targeted radiation (TMLI) with two chemotherapy drugs. The goal is to find the safest dose that can kill …

This study tests whether adding the immunotherapy drug pembrolizumab to standard treatment (azacitidine and venetoclax) helps older adults with newly diagnosed acute myeloid leukemia (AML) achieve deeper remissions and lower the chance of the cancer returning. About 60 participan…

This early-phase trial tests a new drug (navtemadlin) combined with two standard drugs (decitabine and venetoclax) in adults with acute myeloid leukemia that has come back or not responded to treatment. The main goals are to find the safest dose and check for side effects. About …

This early-phase study tests a new antibody called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The main goal is to find a safe dose and check for side effects. Researchers hope the antibody can slow or stop cancer growth.

This early-stage study tests a new type of immunotherapy for people with certain leukemias that have come back or not responded to standard treatment. The therapy uses a patient's own or donor's immune cells that are genetically modified to recognize and attack cancer cells carry…

This study tests a chemotherapy drug called CPX-351 in people under 60 with secondary acute myeloid leukemia (AML), a type of leukemia that develops after other bone marrow diseases or cancer treatments. The goal is to see how many patients achieve complete remission. 21 particip…

This study tests whether adding a drug called decitabine to standard chemotherapy can improve remission rates in adults with acute myeloid leukemia (AML) that is harder to treat. About 178 participants will receive either low or high dose decitabine alongside chemo drugs daunorub…

This early-phase study tests the safety and best dose of combining bortezomib, sorafenib, and decitabine for adults with acute myeloid leukemia (AML). It includes older patients who cannot have standard treatment or those whose leukemia has returned. The goal is to find a tolerab…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) achieve deeper remission. About 49 adults with AML, including those whose cancer arose from prior conditions, will receive …

This early-stage study tests a combination of two drugs—ipilimumab, which boosts the immune system to attack cancer, and decitabine, a chemotherapy drug—in people whose myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has returned or not responded to prior treatment…

This study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, in 133 adults aged 60 and older with untreated acute myeloid leukemia (AML). The goal was to see if the combination could safely lead to complete remission (no signs of cancer) and improve surviv…

This study looks at whether cognitive behavioral therapy (CBT) can help people with acute myeloid leukemia (AML) or lymphoma who feel very tired from their cancer or treatment. About 48 patients will take part in up to 7 counseling sessions to learn new ways to cope with fatigue.…